Published:
Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
CRANBURY, N.J., Aug. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics
(Nasdaq: FOLD), today announced Chief Operating Officer Matthew Patterson will
make a presentation at the BioCentury NewsMakers in the Biotech Industry
Conference on Thursday, September 4, 2008 at 2:30 p.m. EDT in Room 402/403
with a breakout session immediately following the presentation in Room 401.
The conference will be held at Millennium Broadway Hotel & Conference Center
inNew York.
A webcast and audio archive of the presentation will be available at
http://www.amicustherapeutics.com. Participants should allow approximately
five to ten minutes prior to the presentation's start time to visit the site
and download any streaming media software needed to listen to the Internet
webcast. A replay of the webcast will also be available on the Company's Web
site for 30 days until October 4, 2008.
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing novel, oral
therapeutics known as pharmacological chaperones for the treatment of a range
of human genetic diseases. Pharmacological chaperone technology involves the
use of small molecules that selectively bind to and stabilize proteins in
cells, leading to improved protein folding and trafficking, and increased
activity. Amicus is initially targeting lysosomal storage disorders, which are
severe, chronic genetic diseases with unmet medical needs. Amicus has
completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease
and is conducting Phase 2 clinical trials of Plicera for the treatment of
Gaucher disease and AT2220 for the treatment of Pompe disease.
FOLD-G
SOURCE Amicus Therapeutics
Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze,
Daily NewsTags: ,HEA,BIO,MTC,CCA,TDS,NJ-Amicus-Conference
_ _Is your favorite bookmark site missing?
Ask for it.
Search News
Daily News
